Item 8.01 Other Events.

On May 29, 2020, Agios Pharmaceuticals, Inc. (the "Company") issued a press release announcing updated data from the ongoing phase 1 study evaluating single agent vorasidenib in isocitrate dehydrogenase-mutant advanced solid tumors, including glioma. The Company presented data from the non-enhancing glioma population at the American Society of Clinical Oncology (ASCO) Annual Meeting. The full text of the press release issued in connection with this announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits.

 Exhibit
   No.           Description

   99.1            Press release issued May 29, 2020.

   104           Cover Page Interactive Data File (embedded within the Inline XBRL
                 document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses